Sangui Biotech International Stock EBITDA
| SGBI Stock | USD 0 0.00 0.00% |
Sangui Biotech International fundamentals help investors to digest information that contributes to Sangui Biotech's financial success or failures. It also enables traders to predict the movement of Sangui Pink Sheet. The fundamental analysis module provides a way to measure Sangui Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangui Biotech pink sheet.
Sangui |
Sangui Biotech International Company EBITDA Analysis
Sangui Biotech's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Sangui Biotech EBITDA | (18.44 K) |
Most of Sangui Biotech's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangui Biotech International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, Sangui Biotech International reported earnings before interest,tax, depreciation and amortization of (18,443). This is 100.0% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 100.0% higher than that of the company.
Sangui EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangui Biotech's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sangui Biotech could also be used in its relative valuation, which is a method of valuing Sangui Biotech by comparing valuation metrics of similar companies.Sangui Biotech is currently under evaluation in ebitda category among its peers.
Sangui Fundamentals
| Return On Asset | -0.64 | |||
| Profit Margin | (1.27) % | |||
| Operating Margin | (1.50) % | |||
| Current Valuation | 1.68 M | |||
| Shares Outstanding | 209.9 M | |||
| Shares Owned By Insiders | 13.03 % | |||
| Price To Earning | (18.33) X | |||
| Price To Book | 46.44 X | |||
| Price To Sales | 10.09 X | |||
| Revenue | 69.19 K | |||
| Gross Profit | 69.19 K | |||
| EBITDA | (18.44 K) | |||
| Net Income | (63.34 K) | |||
| Cash And Equivalents | 30.47 K | |||
| Total Debt | 48.9 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 0.07 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (140.46 K) | |||
| Beta | 0.22 | |||
| Market Capitalization | 902.58 K | |||
| Total Asset | 130.79 K | |||
| Retained Earnings | (37 M) | |||
| Net Asset | 130.79 K |
About Sangui Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangui Biotech International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangui Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangui Biotech International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Sangui Pink Sheet
Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.